Araújo A, et al. An economic analysis of erlotinib, docetaxel, pemetrexed and best supportive care as second or third line treatment of non-small cell lung cancer Rev Port Pneumol 2008; 14(6):803–827
Araújo A, et al. Avaliação económica do erlotinib, docetaxel, pemetrexedo e tratamento de suporte no tratamento de segunda ou terceira linhas de doentes com cancro do pulmão de não pequenas células Rev Port Pneumol 2008; 14(6):803–827
Wojciech Bartminski
European Outcomes Research, Health Outcomes Scientist, Oncology & Neuroscience, EMS AREA
Read
596
Timeswas read the article
336
Total PDF
260
Total HTML
| Year/Month | Html | Total | |
|---|---|---|---|
| 2024 July | 4 | 4 | 8 |
| 2024 June | 19 | 21 | 40 |
| 2024 May | 21 | 37 | 58 |
| 2024 April | 22 | 17 | 39 |
| 2024 March | 20 | 14 | 34 |
| 2024 February | 18 | 23 | 41 |
| 2024 January | 17 | 28 | 45 |
| 2023 December | 13 | 14 | 27 |
| 2023 November | 22 | 29 | 51 |
| 2023 October | 12 | 30 | 42 |
| 2023 September | 15 | 28 | 43 |
| 2023 August | 23 | 25 | 48 |
| 2023 July | 18 | 27 | 45 |
| 2023 June | 13 | 8 | 21 |
| 2023 May | 18 | 24 | 42 |
| 2023 April | 5 | 7 | 12 |
Show all
